We will be comparing the differences between Quanterix Corporation (NASDAQ:QTRX) and EyeGate Pharmaceuticals Inc. (NASDAQ:EYEG) as far as dividends, analyst recommendations, institutional ownership, profitability, risk, earnings and valuation are concerned. The two businesses are rivals in the Biotechnology industry.

Valuation & Earnings

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Quanterix Corporation	37.63M	15.36	31.54M	-2.07	0.00
EyeGate Pharmaceuticals Inc.	1.65M	9.24	10.81M	-0.45	0.00

In table 1 we can see Quanterix Corporation and EyeGate Pharmaceuticals Inc.’s gross revenue, earnings per share and valuation.

Profitability

Table 2 hightlights the return on equity, net margins and return on assets of the two companies.

	Net Margins	Return on Equity	Return on Assets
Quanterix Corporation	-83.82%	-53.8%	-37.5%
EyeGate Pharmaceuticals Inc.	-655.15%	-158.8%	-72.7%

Liquidity

4.1 and 3.8 are the respective Current Ratio and a Quick Ratio of Quanterix Corporation. Its rival EyeGate Pharmaceuticals Inc.’s Current and Quick Ratios are 2.5 and 2.5 respectively. Quanterix Corporation has a better chance of clearing its pay short and long-term debts than EyeGate Pharmaceuticals Inc.

Insider and Institutional Ownership

Quanterix Corporation and EyeGate Pharmaceuticals Inc. has shares owned by institutional investors as follows: 70.8% and 49.8%. Insiders owned roughly 11.9% of Quanterix Corporation’s shares. Comparatively, insiders own roughly 14.69% of EyeGate Pharmaceuticals Inc.’s shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
Quanterix Corporation	1.89%	17.57%	38.09%	65.18%	20.43%	35.23%
EyeGate Pharmaceuticals Inc.	0.23%	-9.52%	-17.29%	-22.3%	-25.59%	-5.61%

For the past year Quanterix Corporation has 35.23% stronger performance while EyeGate Pharmaceuticals Inc. has -5.61% weaker performance.

Summary

Quanterix Corporation beats EyeGate Pharmaceuticals Inc. on 8 of the 10 factors.

Quanterix Corporation, a life sciences company, develops and markets ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and Asia Pacific. It develops Simoa HD-1 Analyzer, a sensitive protein detection platform, which analyzes approximately six biomarkers per test; and SR-X system that supports the detection capability of approximately six biomarkers per test. The company's products also comprise kits, such as beads, capture and detector reagents, enzyme reagents, and enzyme substrates to run tests; and consumables, such as proprietary Simoa disks, cuvettes, and disposable tips. In addition, it offers contract research services, including sample testing, assay development, and custom development services. Quanterix Corporation primarily operates in the areas of neurology, oncology, cardiology, infectious diseases, and inflammation. The company was formerly known as Digital Genomics, Inc. and changed its name to Quanterix Corporation in August 2007. Quanterix Corporation was incorporated in 2007 and is headquartered in Lexington, Massachusetts.

EyeGate Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, focuses on developing and commercializing drug compositions and drug delivery systems for treating diseases and disorders of the eye. The company is developing EGP-437 for the treatment of various inflammatory conditions of the eye, including the treatment of ocular inflammation and pain in post-surgical cataract patients; and uveitis, a debilitating form of intraocular inflammation of the anterior portion of the uvea. It is also developing the EyeGate Ocular Bandage Gel, a topically-applied eye drop formulation that has completed its first-in-man clinical trial for the management of corneal epithelial defects, as well as to accelerate re-epithelization of the ocular surface following surgery, injection, and other traumatic and non-traumatic conditions. In addition, the company is developing Eyegate II drug delivery system. It has license agreements with the University of Miami and its School of Medicine; subsidiaries of Valeant Pharmaceuticals International, Inc.; BioTime, Inc.; and the University of Utah Research Foundation. Eyegate Pharmaceuticals, Inc. is headquartered in Waltham, Massachusetts.